
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is a growing pharmaceutical company with a strong portfolio of marketed drugs and an exciting pipeline focused on both oncology and dermatology. Their partnerships with Novartis and Lilly provide valuable support and potential for further growth. Risks include potential setbacks in clinical trials and slower market uptake, but overall, the company's positive outlook and continued pipeline success make it an attractive investment opportunity.
Bears say
Incyte is facing challenges in expanding its potential market for its leading drug, Jakafi, as data from its Phase 3 study in 2L ET is only expected in late 2028 or early 2029. The company's pipeline includes promising oncology and dermatology programs, but there are concerns about the time and investment needed to bring these treatments to market. An expansion of Opzelura's EU label into moderate AD, coupled with its sales growth in the US market, may help mitigate some of these concerns and drive future revenue growth for the company.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares